Background and Objectives: Stroke is a disease with high morbidity, disability, and fatality. Since ischemic stroke is the most common kind of stroke, increasing attention has been paid to its prevention and treatment. Given the limitations of conventional medicine, there is growing interest in Chinese Medicine (CM), especially Chinese Patent Medicine (CPM) for its convenience and stability. Studies of CM show that Chinese Patent Medicines for Tonifying Qi and Promoting Blood Circulation (CPMs-TQPBC) are one of the most common and effective categories of all clinical CPMs in China.
Methods: This review investigated and summarized the randomized controlled trials (RCT) of CPMs-TQPBC combined with conventional interventions in the last 10 years.
Results: Trial results demonstrated the potential in reducing the endpoints and improving neurologic impairments, body movements, Barthel index, quality of life, and certain biomarkers. Furthermore, certain CM syndromes were alleviated with rare adverse events. Advantages of interventions combined with CPMs-TQPBC for patients with cerebral infarction were discovered. Compared with the Chinese patent medicines for promoting blood circulation (CPMs-PBC) alone, CPMs for both tonifying qi and promoting blood circulation exhibited noticeably better effects. The underlying reasons could be related to the improvement of microcirculation in the brain, protection against ischemic reperfusion injury, generation of neuroprotective factors, and inhibition of apoptosis.
Conclusion: Under the circumstances of qi deficiency and blood stasis syndrome (QDBSS) (Qixu-Xueyu Zheng), CPMs- TQPBC showed a substantial difference. More trials focusing on specific patient groups should be carried out to corroborate and expand the findings.
Keywords: Cerebral infarction, tonifying qi and promoting blood circulation, chinese patent medicine, review.
HSP27 Protects the Blood-Brain Barrier Against Ischemia-Induced Loss of Integrity
CNS & Neurological Disorders - Drug Targets A Lipid Anchor Improves the Protective Effect of Ectoine in Inflammation
Current Medicinal Chemistry Pro-rich Antimicrobial Peptides from Animals: Structure, Biological Functions and Mechanism of Action
Current Pharmaceutical Design Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice
Current Molecular Medicine Cannabinoid CB2 Receptors in Health and Disease
Current Medicinal Chemistry Comprehensive Review on Custodiol-N (HTK-N) and its Molecular Side of Action for Organ Preservation
Current Pharmaceutical Biotechnology Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology The Protective Role of Steroids in Ischemia-Reperfusion Injury of the Liver
Current Pharmaceutical Design Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Protective Effects of Intermedin On Cardiovascular, Pulmonary and Renal Diseases: Comparison with Adrenomedullin and CGRP
Current Protein & Peptide Science Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Diagnostic and Therapeutic Patents and Patent Applications on Biomarkers for Acute Kidney Injury
Recent Patents on Biomarkers (Discontinued) Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Heparins with Reduced Anti-Coagulant Activity Reduce Myocardial Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Current Drug Targets Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Current Molecular Medicine SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets HIF-1α as a Target for Drug Design in Ischemic Injury: Effect of Cobalt Treatment on Mitochondrial DNA Damage in Cells Exposed to H2O2
Letters in Drug Design & Discovery The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry